Monopar Therapeutics Inc

This stock has a reasonable momentum. Monopar Therapeutics Inc is not a good value stock. Monopar Therapeutics Inc is a mediocre stock to choose.
Log in to see more information.
MNPR Fundamental Data by TradingView

News

Monopar Therapeutics regains compliance with Nasdaq minimum bid price rule
Monopar Therapeutics regains compliance with Nasdaq minimum bid price rule

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Globe Newswire WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...\n more…

HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $6.00
HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $6.00

Ticker Report Monopar Therapeutics (NASDAQ:MNPR - Free Report) had its target price increased by HC Wainwright from $2.00 to $6.00 in a research report released on Wednesday morning, Benzinga reports. The...\n more…

Monopar Therapeutics target adjusted to $9 from $2 at JonesResearch
Monopar Therapeutics target adjusted to $9 from $2 at JonesResearch

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Buy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial Positioning
Buy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial Positioning

TipRanks Financial Blog In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR - Research Report), with a pri...\n more…

Monopar Therapeutics Inc. Forecasted to Earn Q3 2024 Earnings of ($2.60) Per Share (NASDAQ:MNPR)
Monopar Therapeutics Inc. Forecasted to Earn Q3 2024 Earnings of ($2.60) Per Share (NASDAQ:MNPR)

Zolmax Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2024 earnings estimates for Monopar Therapeutics in a report issued on Monday...\n more…